Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**CH-BPNs-NBP** is an injectable thermosensitive chitosan hydrogel formulation containing black phosphorus nanosheets and dl-3-n-butylphthalide. It is being investigated as a local treatment for periodontitis, including diabetic periodontitis. The black phosphorus nanosheets provide reactive oxygen species-scavenging activity, while dl-3-n-butylphthalide is intended to support jaw vascular-unit and lymphatic function. In preclinical periodontitis models, the formulation reduced oxidative stress and inflammation, promoted macrophage polarization toward an M2 phenotype, improved iron-homeostasis markers, protected lymphatic endothelial cells, and reduced alveolar bone loss.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CH-BPNs-NBP.